The maximum dose of Pulmazole planned to be administered in this study was 35 mg itraconazole (70 mg dry powder including excipients). A total of 23 subjects were dosed across 4 cohorts (5 mg, 10 mg, ...

The Pulmatrix Pulmazole program is the first inhaled dry powder version of itraconazole known to the company to be advanced into clinical development, with the goal of improving upon the known ...

LEXINGTON, Mass., June 25, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative i ...

Inhaled Itraconazole Therapies: Biopharmaceutical companies are developing inhalable dry powder formulations of itraconazole to treat Allergic Bronchopulmonary Aspergillosis (ABPA) in asthma patients.

October 9, 2009 — Monthly cycle–dependent itraconazole is more effective than classic homeopathy for treating recurrent vulvovaginal candidiasis (RVVC), according to the results of a single ...

The technology is a dry powder delivery platform that allows ... a phase 1/1b study of PUR1900 demonstrating an approximately 50-fold higher lung delivery at 1/10th the dosing of oral itraconazole.